According to the Cancer Statistics of 2024, approximately 20 million people worldwide are newly diagnosed with cancer each year. By 2030, this number is projected to double if not properly controlled. A significant issue is the lack of testing for early diagnosis, prognosis, and treatment follow-up. In some Southeast Asian countries, such as India, around 40% of cancer patients are diagnosed at a metastatic stage due to inadequate testing. Nearly all cancer-related deaths are caused by metastasis, and currently, there is no effective therapy for metastatic cancer.

At GeneVerify, Inc., our professionals believe that early identification and intervention, specifically targeting a set of oncogenes, can inhibit cancer progression and metastasis. These cutting-edge technologies will improve patient outcomes while simultaneously reducing healthcare costs.

We have developed a novel blood-based mRNA genomic technology, which holds 5 U.S. patents and has been featured in over 200 original research publications in high-impact journals.

Our blood-based mRNA genomic technology can be utilized for screening, early diagnosis, prognosis, treatment follow-up, and gene therapy for various cancers. These tests have undergone 9 clinical trials across 9 hospitals in the USA, Japan, and India, demonstrating 95% specificity and sensitivity.

Our team consists of more than 50 medical scientists with expertise in medical oncology, surgical oncology, pathology, radiation oncology, molecular biology, genetics, gene therapy, cancer biology, and biochemistry, who have been working in the USA for the past 20 to 40 years.

On January 25-27^th, 2024, we presented our data at the ASCO GU symposium (American Society of Clinical Oncology) meeting at San Francisco, California, USA. ASCO has 45,000 members worldwide. This paper was published in the Journal of Clinical Oncology January 29^th 2024.

https://ascopubs.org/doi/10.1200/JCO.2024.42.4_suppl.271

On April 5-10, 2024, we presented our data at the AACR meeting (American Association of Cancer Research) at San Diego, CA. AACR has 58,000 members from 141 countries (google search). This paper was published in the Journal “CANCER RESEARCH” March 22, 2024.

https://aacrjournals.org/cancerres/article/84/6_Supplement/2442/741209/Abstract-2442-Blood-based-novel-mRNA-genomic-test

On May 3-6, 2024 we presented our data at AUA (American Urology Association) at San Antonio, Texas. AUA has more than 25,000 members from 138 counties (google search). This paper was published in the Journal “Journal of Urology” May, 2024.

https://www.auajournals.org/doi/10.1097/01.JU.0001008896.93851.5b.05  

It has following advantages:

1. Screening and early diagnosis when pathological and clinical findings fail to detect cancer. Based on the recent publications 25% of patients that are normal pathologically and clinically, in fact they have cancer based on genetic testing. Most patients die of cancer due to metastasis and if detected early 90% cancer patients can be cured or prolong their lives.
2. Avoidance of surgery, if the tumor is slow growing, then it can be on active surveillance. Based on published data, 50% of surgeries may not be required since it is misdiagnosed.  
3. Prognosis of cancer based on genetic profile. If a tumor is aggressive then more aggressive treatments are needed. If the tumor is slow growing then less aggressive intervention is required. Most patients die due to aggressive treatments that may not be required if the tumor is slow growing.
4. Monitoring of treatment whether the treatments are effective or not. Genetic testing will closely monitor effectiveness of expensive therapies. This will save lives of many patients by undue treatments and save millions of dollars since these therapies may not be working.
5. To start phase 1 clinical trial of gene therapy using antisense technology. We have a US patent on this technology. Our approach is gene-based diagnosis through genetic profiling and gene-based therapy through inhibition of cancer genes by antisense technology.

GeneVerify’s targeted genetic testing kits are the path to value-based rapid testing, discovery and identification, and risk prediction that is invaluable to early intervention.

Backed by our genetic testing profiling, medical oncologists and surgical oncologists may enable to (i) diagnose early stage cancer (ii) predict whether tumor is aggressive or slow growing and thus provide better decisions for surgery or active surveillance (iii) predict prognosis and risk assessment of cancer based on genetic profiling (iv) better predict how a patient might respond to certain modalities and therapies more accurately, and (v) achieve a solid basis for better decision-making on a patient’s therapeutic treatment and future evaluation to yield the quickest results, thereby enhancing your patient’s health, lengthen life, and reduce illness and disability.

 At GeneVerify, Inc., we are tackling the issues that matter most to patient care in a collaborative setting where teamwork and innovation leads to more answers.